In this research, resveratrol (RSV)‐loaded scaffolds have been prepared to control the release of resveratrol and used to delay hepatic stellate cell (HSC) senescence in vitro. The functional carboxyl group–COOH is first introduced to the surface of poly(ε‐caprolactone/d,l‐lactide) (P(CL‐DLLA)) under the coadministration of ultra‐violet (UV) treatment and photo initiator and then resveratrol are conjugated onto the surface of the modified scaffolds through esterification. The characterization of the structure of RSV‐AA‐P(CL‐DLLA) shows that resveratrol has been successfully conjugated onto the modified surface. Cell growth exhibits a higher level of cell viability and much more obvious agglomeration on the surface of the synthetic RSV‐AA‐P(CL‐DLLA). Meanwhile the activity of senescence‐associated β‐galactosidase (SA‐β‐gal) and reactive oxygen species (ROS) is downgulated for cells on RSV‐AA‐P(CL‐DLLA), which suggests that cell senescence is delayed on RSV‐AA‐P(CL‐DLLA). And then it is attested that cells have a lower level of p53 but SIRT1 expression is upregulated on RSV‐AA‐P(CL‐DLLA), which might be related to resveratrol release from RSV‐AA‐P(CL‐DLLA). It also suggested cell senescence on RSV‐AA‐P(CL‐DLLA) has been regulated by p53 and the SIRT1 signaling pathway. In all, the present study shows that RSV‐AA‐P(CL‐DLLA) can be successfully prepared to promote cell growth and delay cell senescence and could be used for cell‐based therapy in tissue engineering. RSV‐AA‐P(CL‐DLLA) is fabricated with the introduction of the functional carboxyl group–COOH) onto the surface of poly(ε‐caprolactone/d,l‐lactide) P(CL‐DLLA)) and esterification of resveratrol with the modified surface. The synthetic scaffold is used to delay cell senescence in cell‐based therapy tissue engineering.